T cell epitope mapping of secukinumab and ixekizumab in healthy donors

Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vitro immunogenicity potential compared with other mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spindeldreher, Sebastian, Karle, Anette, Correia, Evelyne, Tenon, Maxime, Gottlieb, Sascha, Huber, Thomas, Maillere, Bernard, Kolbinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648323/
https://www.ncbi.nlm.nih.gov/pubmed/31924123
http://dx.doi.org/10.1080/19420862.2019.1707418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648323/
https://www.ncbi.nlm.nih.gov/pubmed/31924123
http://dx.doi.org/10.1080/19420862.2019.1707418

Ejemplares similares